- GBI & PARTNERS
- Gan & Lee Pharma teams with IDF and Wechat
Gan & Lee Pharma teams with IDF and Wechat
China-based Gan & Lee Pharmaceuticals (603087.SH) unveiled a partnership with the International Diabetes Federation (IDF) and will provide support to the IDF on diabetes prevention and treatment worldwide. The deal means Gan & Lee Pharma will provide medical education in the IDF diabetes school, back IDF's official Wechat account launch, and have the opportunity to partake in World Diabetes Day and the Centennial of Insulin event among other campagns. No financial details were disclosed.
The IDF Diabetes Atlas indicates that there were 463 million adult (aged 20-79) diabetes sufferers in 2019, and that tally is expected to reach 700 million by 2045. In addition, 1 in every 2 diabetes cases went undiagnosed in 2019, necessitating the publicity and educational drive. Gan & Lee and IDF will focus on global diabetes publicity and promotion campaigns to improve the quality of life for patients.
Gan & Lee was the first domestic firm capable of manufacturing recombinant insulins in China. Its portfolio includes long-acting insulin glargine injection, quick-acting insulin lispro injection, quick-acting insulin aspart injection, protamine zinc recombinant insulin lispro injection (25R), and the recently approved insulin aspart 30 injection.
- Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua